Clinical trial
The AIRWARD Study: A Phase III, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate the Efficacy and Safety of Verducatib in Participants With COPD
NCT07907991 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The AIRWARD Study: A Phase III, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate the Efficacy and Safety of Verducatib in Participants With COPD
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- March 10, 2027
- Completion date
- December 10, 2029
- Enrollment
- 1,800 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease
Arms
As registered; 2 arms.
-
Verducatib treatment group
-
Placebo group
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Annualised rate of moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (number of events per person per year)
Lead sponsor's other trials
Boehringer Ingelheim, most recent start first.
+2,298 more trials See the organization page
Similar trials
Same condition (Pulmonary Disease, Chronic Obstructive) and phase, most recent start first.
+498 more trials See the condition page